Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Lung Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × bavituximab × Clear all
NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Peregrine Pharmaceuticals

Phase 2/3 Withdrawn
Breast

Breast Neoplasms

NCT00669591 2017-04-21

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
46 enrolled
Breast

Breast Neoplasms

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00669565 2011-03-24

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
46 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡